Oncternal Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James B. Breitmeyer
- Full Time Employees
- 27
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12230 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Feb 3, 2004
- CIK
- 0001260990
- Website
- oncternal.com
- Similar Companies
- Business
- Oncternal Therapeutics, Inc., a former clinical-stage biopharmaceutical company, concluded its active drug development efforts for oncology therapies targeting critical unmet medical needs. The company recently completed the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc.. Zilovertamab was an investigational humanized monoclonal antibody designed to bind to Receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1), while ONCT-808 was a chimeric antigen receptor T-cell (CAR-T) product candidate also targeting ROR1.. Prior to this divestiture, Oncternal had discontinued clinical trials for ONCT-534, a dual-action androgen receptor inhibitor aimed at castration-resistant prostate and other androgen receptor-driven cancers, and ONCT-808, due to interim results and capital considerations.. The company's pipeline also previously included ONCT-216, a small molecule inhibiting ETS-family transcription factor oncoproteins.. Oncternal Therapeutics, Inc. announced its intention to voluntarily delist its common stock from Nasdaq and deregister with the SEC, with trading having been suspended.. The company is currently in the process of winding down its operations, with leadership focused on overseeing this transition and the distribution of remaining assets and potential future milestone payments.. The company was headquartered in San Diego, California.
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results